Allogeneic adoptive cell transfer therapy as a potent universal treatment for cancer

Assaf Marcus; Zelig Eshhar

doi:10.18632/oncotarget.300

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access, weekly journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial Introducing OncoTarget.

Request Conference Sponsorship

Editorial:

Allogeneic adoptive cell transfer therapy as a potent universal treatment for cancer

Assaf Marcus and Zelig Eshhar _

PDF | HTML | How to cite | Order a Reprint

Oncotarget. 2011; 2:525-526. https://doi.org/10.18632/oncotarget.300

Metrics: PDF 1673 views | HTML 2393 views | ?

Abstract

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 300

Subscribe to TOC Alerts

Editorial:

Allogeneic adoptive cell transfer therapy as a potent universal treatment for cancer

Abstract